DNA services/adaptive biotechnologies/malekzadeh
Ended Purchase Order Awarded Last action
- Contract number
- HHSN261201800129P
- Awardee
-
Adaptive Biotechnologies Corporation UEI DMW5BNQ331K9
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,088
Award facts
- Contract value 100% obligated
- $5,087.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Piscataway, NJ 08854, USA
Award details come from SAM.gov/FPDS.
About this award
The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $5,087.50 on January 24, 2018, with ultimate completion on February 24, 2018. Work is performed in Piscataway, New Jersey. The order covers DNA services under firm fixed-price pricing with no set-aside applied.
Quick answers
Who was awarded contract HHSN261201800129P?
HHSN261201800129P was awarded to Adaptive Biotechnologies Corporation by National Cancer Institute (National Institutes of Health) on January 24, 2018.
How much is contract HHSN261201800129P worth?
The government has obligated $5,088 on HHSN261201800129P.
Was contract HHSN261201800129P competed?
The extent of competition for HHSN261201800129P was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award